COMMUNIQUÉS West-GlobeNewswire

NTG Nordic Transport Group A/S - Q3 2025 Conference Call
10/10/2025
NTG Nordic Transport Group A/S – Q3 2025 Conference Call We expect to release the Q3 2025 interim results of NTG Nordic Transport Group on the evening of November 10, 2025. A webcast and conference call will be held in [...]
Shape Therapeutics Shares Breakthrough Preclinical Data for Non-Invasive Treatment of Parkinson’s Disease Using a Brain Targeted AAV Gene Therapy at the European Society of Gene & Cell Therapy 32nd Annual Congress
10/10/2025
Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's Disease-critical substantia [...]
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
10/10/2025
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR [...]
NeuroVigil’s iBrain™ in TIME’s “Best Inventions of 2025”
10/10/2025
SAN FRANCISCO and WATERLOO, Ontario and MONTREAL and LEIPZIG, Germany, Oct. 09, 2025 (GLOBE NEWSWIRE) -- TIME has announced today that Silicon Valley-based Neurotechnology Powerhouse NeuroVigil’s iBrain™ has been [...]
Executive Wellness Retreats: Grey Matters International Announces Expansion of Neuroscience-Based Programs
09/10/2025
Tulsa, Oklahoma , Oct. 09, 2025 (GLOBE NEWSWIRE) -- Grey Matters International, Inc. , a neuroscience-driven mental health organization founded by Kevin J. Fleming, Ph.D., today announced the expansion of its executive [...]
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
09/10/2025
ACTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced [...]
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
09/10/2025
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 [...]
Procedure of the Annual General Meeting
09/10/2025
ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General [...]
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/10/2025
REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance
09/10/2025
Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., Oct. 09, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) ( [...]
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
09/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran
09/10/2025
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
09/10/2025
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, [...]
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
09/10/2025
GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today [...]
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
09/10/2025
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural [...]
Clover Health Comments on 2026 Medicare Advantage Star Ratings and Trajectory for Increasing Profitability into 2027
09/10/2025
Company underscores differentiated business model; reiterates confidence in its ability to drive above-market membership growth and increasing Adjusted EBITDA profitability 1 through 2027, independent of Star ratings [...]
VitalHub Announces Novari Health Deployment in the UK
09/10/2025
TORONTO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") announced that Novari Health (“Novari”), a VitalHub company, has been commissioned for its first UK [...]
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
09/10/2025
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients [...]
Portsmouth Square, Inc. Announces FY2025 Results; Going-Concern Doubt Alleviated Following March 2025 Hotel Refinancing and Strong Operating Trends
09/10/2025
Los Angeles, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. ("Portsmouth" or the "Company") (OTC: PRSI) reported results for the fiscal year ended June 30, 2025 and announced that the substantial doubt [...]

Pages